Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI trial
Thomas J George, Tuo Lin, Ibrahim Nassour, Sherise C. Rogers et autres
0 citationsThe Oncologist
Anita Turk
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
101Publications signalées
1405Citations signalées
4Affiliations récentes
Institutions déclarées
Domaines associés
Pancreatic and Hepatic Oncology ResearchColorectal Cancer Treatments and StudiesCancer Immunotherapy and BiomarkersCholangiocarcinoma and Gallbladder Cancer StudiesMicroscopic Colitis
Publications récentes
Data from Tumor Matrix Proteoglycan Accumulation and Processing Alter T-cell Effector Function and the Response to Immunotherapy in Patients with Oligometastatic Colorectal Cancer
Dustin A. Deming, Sean G. Kraus, Joshua Brand, Katherine A. Johnson et autres
0 citations
Supplementary Figures S1-S14 from Tumor Matrix Proteoglycan Accumulation and Processing Alter T-cell Effector Function and the Response to Immunotherapy in Patients with Oligometastatic Colorectal Cancer
Dustin A. Deming, Sean G. Kraus, Joshua Brand, Katherine A. Johnson et autres
0 citations
Clinical Trial Protocol from Tumor Matrix Proteoglycan Accumulation and Processing Alter T-cell Effector Function and the Response to Immunotherapy in Patients with Oligometastatic Colorectal Cancer
Dustin A. Deming, Sean G. Kraus, Joshua Brand, Katherine A. Johnson et autres
0 citations
Supplementary Tables S1-S6 from Tumor Matrix Proteoglycan Accumulation and Processing Alter T-cell Effector Function and the Response to Immunotherapy in Patients with Oligometastatic Colorectal Cancer
Dustin A. Deming, Sean G. Kraus, Joshua Brand, Katherine A. Johnson et autres
0 citations
Ketogenic supplementation enhances KRASG12D inhibitor efficacy in pancreatic ductal adenocarcinoma
Loan Duong, Julim Lee, Yujing Qin, Nipuni P. Barupala et autres
0 citationsCancer Letters
Data from Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations
James J. Harding, Do‐Youn Oh, Teresa Macarulla, Lipika Goyal et autres
0 citations
Supplementary Data 1 from Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations
James J. Harding, Do‐Youn Oh, Teresa Macarulla, Lipika Goyal et autres
0 citations
Protocol of a randomized trial of acceptance and commitment therapy for patient fatigue interference and caregiver burden in advanced gastrointestinal cancer
Catherine E. Mosher, Eileen H. Shinn, Elizabeth L. Addington, Wei Wu et autres
0 citationsContemporary Clinical Trials
ASO Visual Abstract: Association Between Fragmentation of Care and Delivery of Adjuvant Chemotherapy in Patients Traveling to High-Volume Hospitals for Pancreatic Adenocarcinoma
Alexa J. Hughes, Kristen N. Kaiser, Emma Holler, Brian Ruedinger et autres
0 citationsAnnals of Surgical Oncology
Association Between Fragmentation of Care and Delivery of Adjuvant Chemotherapy in Patients Traveling to High-Volume Hospitals for Pancreatic Adenocarcinoma
Alexa J. Hughes, Kristen N. Kaiser, Emma Holler, Brian Ruedinger et autres
1 citationAnnals of Surgical Oncology
Treatment delays and risk of metastatic progression in colorectal cancer patients undergoing curative surgery: Real-world evidence from a national claims database.
Chi M. Nguyen, Todd C. Skaar, Thomas F. Imperiale, Anita Turk et autres
0 citationsJCO Oncology Practice
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.